Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-25.67%
operating margin TTM
-28.14%
revenue TTM
11.32 Million
revenue per share TTM
0.27$
valuation ratios | |
|---|---|
| pe ratio | -2.57 |
| peg ratio | -0.07 |
| price to book ratio | 1.45 |
| price to sales ratio | 0.11 |
| enterprise value multiple | -2.92 |
| price fair value | 1.45 |
profitability ratios | |
|---|---|
| gross profit margin | 95.26% |
| operating profit margin | -28.14% |
| pretax profit margin | -28.42% |
| net profit margin | -25.67% |
| return on assets | -14.15% |
| return on equity | -74.84% |
| return on capital employed | -19.39% |
liquidity ratio | |
|---|---|
| current ratio | 3.85 |
| quick ratio | 3.82 |
| cash ratio | 1.84 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 82.37 |
| operating cycle | 162.88 |
| days of payables outstanding | 398.60 |
| cash conversion cycle | -235.72 |
| receivables turnover | 4.53 |
| payables turnover | 0.92 |
| inventory turnover | 4.43 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | 0.31 |
| long term debt to capitalization | 0.20 |
| total debt to capitalization | 0.24 |
| interest coverage | -30.04 |
| cash flow to debt ratio | -2.18 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.04 |
| cash per share | 0.12 |
| operating cash flow per share | -0.03 |
| free cash flow operating cash flow ratio | 1.04 |
| cash flow coverage ratios | -2.18 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -22.59 |
Frequently Asked Questions
When was the last time Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported earnings?
Adaptimmune Therapeutics plc (ADAP) published its most recent earnings results on 13-11-2024.
What is Adaptimmune Therapeutics plc's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Adaptimmune Therapeutics plc (NASDAQ:ADAP)'s trailing twelve months ROE is -74.84%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Adaptimmune Therapeutics plc (ADAP) currently has a ROA of -14.15%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did ADAP's net profit margin stand at?
ADAP reported a profit margin of -25.67% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is ADAP's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 3.85 in the most recent quarter. The quick ratio stood at 3.82, with a Debt/Eq ratio of 0.31.